Needham Upgrades ResMed to Buy, Announces $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has upgraded ResMed (NYSE:RMD) from Hold to Buy and announced a price target of $180.
September 06, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ResMed has been upgraded from Hold to Buy by Needham analyst Mike Matson, with a new price target of $180.
The upgrade from Hold to Buy by Needham analyst Mike Matson indicates a positive outlook for ResMed. The new price target of $180 suggests that the analyst expects the stock to rise in the short term. This could potentially lead to an increase in the stock's price as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100